Robustness of CSF Aβ42/40 and Aβ42/P‐tau181 measured using fully automated immunoassays to detect AD‐related outcomes
Alzheimer's & Dementia · 2023-07 · 19 (7) · 2994-3004
DOI: 10.1002/alz.12897 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 21.01.2023. Verfasst von Antoine Leuzy und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Vetenskapsrådet, Hjärnfonden.
Abstract (Originalsprache)
Introduction
This study investigated the comparability of cerebrospinal fluid (CSF) cutoffs for Elecsys immunoassays for amyloid beta (Aβ)42/Aβ40 or Aβ42/phosphorylated tau (p‐tau)181 and the effects of measurement variability when predicting Alzheimer's disease (AD)‐related outcomes (i.e., Aβ‐positron emission tomography [PET] visual read and AD neuropathology).
Methods
We studied 750 participants (BioFINDER study, Alzheimer's Disease Neuroimaging Initiative [ADNI], and University of California San Francisco [UCSF]). Youden's index was used to identify cutoffs and to calculate accuracy (Aβ‐PET visual read as outcome). Using longitudinal variability in Aβ‐negative controls, we identified a gray zone around cut‐points where the risk of an inconsistent predicted outcome was >5%.
Results
For Aβ42/Aβ40, cutoffs across cohorts were
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
- Department of Neurology, Skåne University Hospital, Lund, Sweden.
- Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.
- Memory Clinic, Skåne University Hospital, Malmö, Sweden.
- Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
- Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Förderung
- Vetenskapsrådet
- Hjärnfonden
Zitieren
APA
Leuzy, A., Mattsson-Carlgren, N., Cullen, N. C., Stomrud, E., Palmqvist, S., La Joie, R., Iaccarino, L., Zetterberg, H., Rabinovici, G., Blennow, K., Janelidze, S., & Hansson, O. (2023). Robustness of CSF Aβ42/40 and Aβ42/P‐tau181 measured using fully automated immunoassays to detect AD‐related outcomes. Alzheimer's & Dementia, 19(7), 2994-3004. https://doi.org/10.1002/alz.12897
Vancouver
Leuzy A, Mattsson-Carlgren N, Cullen NC, Stomrud E, Palmqvist S, La Joie R, et al. Robustness of CSF Aβ42/40 and Aβ42/P‐tau181 measured using fully automated immunoassays to detect AD‐related outcomes. Alzheimer's & Dementia. 2023;19(7):2994-3004. doi:10.1002/alz.12897
BibTeX
@article{Leuzy2023,
author = {Leuzy, Antoine and Mattsson-Carlgren, Niklas and Cullen, Nicholas C and Stomrud, Erik and Palmqvist, Sebastian and La Joie, Renaud and Iaccarino, Leonardo and Zetterberg, Henrik and Rabinovici, Gil and Blennow, Kaj and Janelidze, Shorena and Hansson, Oskar},
title = {Robustness of CSF Aβ42/40 and Aβ42/P‐tau181 measured using fully automated immunoassays to detect AD‐related outcomes},
journal = {Alzheimer's & Dementia},
year = {2023},
volume = {19},
number = {7},
pages = {2994--3004},
doi = {10.1002/alz.12897}
}
EUVIMED